Breast Cancer – Page 4 – Medical News Asia

Palbociclib (Ibrance®): First in Class CDK4/6 Inhibitor

17 September 2016/3 Comments/in Breast Cancer, Oncology, Targeted Therapies/by Stijn van den Borne, MSc

At the American Association for Cancer Research, 2014 annual meeting (AACR) Richard Finn presented the results of the PALOMA-1 study with Ibrance® (palbociclib), an oral inhibitor of cyclin-dependent kinase 4/6 (CDK4/6). Based on the results of this Phase 2 study, palbociclib was recently approved by the United States Drug and Food Administration (U.S. FDA). What is the current level of evidence on palbociclib in approved indications?

Ki67 in Breast Cancer: an overview

6 September 2016/3 Comments/in Breast Cancer, Oncology, Surgery, Targeted Therapies, Pathology, Translational Research/by Stijn van den Borne, MSc

Recent studies have shown new possible applications for Ki67. Huh et al. showed that low Ki67 levels in healthy breast tissue correlated with a lesser lifetime chance of breast cancer. Another study by Arnedos and colleagues concluded that palbociclib was able to invoke a significant Ki67-level drop. After a decade of Ki67-controversies, these results put the marker back in the spotlight.